GGrantIndex
← Leaderboards

Srikanta Dash

Tulane University Of Louisiana

$6,178,827
Attributed
$6,178,827
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $613.3K · FY200523
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$6,178,827 · 6
VA$0 · 1

By mechanism

R01$5,798,552 · 4
R21$343,089 · 1
P51$37,186 · 1
I01$0 · 1

Top collaborators

No co-investigators on record.

Most similar at Tulane University Of Louisiana

Same institution · by research overlap

Others in their field

Top investigators on “Hepatitis C Virus

Research focus

Hepatitis C VirusHepatitis CInterferonsAntiviral AgentsMalignant Neoplasm Of LiverPrimary Carcinoma Of The Liver CellsLiverHepatocyteVirus ReplicationSignal TransductionPlayMicrornasResponseLiver CirrhosisViralMediatingInterferon-AlphaResistanceVirus DiseasesGenesRibavirinApplications GrantsBasePublishing

Grant awards (29)

Early Detection of HCC Among Veterans With Liver Cirrhosis$0
I01 · FY2023 · VA · contact PI
Early Detection of HCC Among Veterans With Liver Cirrhosis$0
I01 · FY2022 · VA · contact PI
Early Detection of HCC Among Veterans With Liver Cirrhosis$0
I01 · FY2021 · VA · contact PI
Early Detection of HCC Among Veterans With Liver Cirrhosis$0
I01 · FY2020 · VA · contact PI
Early Detection of HCC Among Veterans With Liver Cirrhosis$0
I01 · FY2019 · VA · contact PI
IL-28B genotype and HCV treatment clearance$376,250
R01 · FY2016 · AI · contact PI
Hepatitis C Virus and Hepatocellular Carcinoma$237,038
R01 · FY2016 · CA · contact PI
IL-28B genotype and HCV treatment clearance$376,250
R01 · FY2015 · AI · contact PI
Hepatitis C Virus and Hepatocellular Carcinoma$237,038
R01 · FY2015 · CA · contact PI
IL-28B genotype and HCV treatment clearance$376,250
R01 · FY2014 · AI · contact PI
Hepatitis C Virus and Hepatocellular Carcinoma$229,927
R01 · FY2014 · CA · contact PI
IL-28B genotype and HCV treatment clearance$353,675
R01 · FY2013 · AI · contact PI
Hepatitis C Virus and Hepatocellular Carcinoma$222,816
R01 · FY2013 · CA · contact PI
Hepatocarcinogenesis Secondary to Hepatitis C$272,731
R01 · FY2012 · CA · contact PI
Hepatitis C Virus and Hepatocellular Carcinoma$237,038
R01 · FY2012 · CA · contact PI
Hepatocarcinogenesis Secondary to Hepatitis C$272,731
R01 · FY2011 · CA · contact PI
HLA-I EXPRESSION AND IFN-GAMMA SIGNALING IN IFN-? RESISTANT HCV REPLICON CELLS$37,186
P51 · FY2011 · RR · contact PI
Hepatocarcinogenesis Secondary to Hepatitis C$281,166
R01 · FY2010 · CA · contact PI
Intracellular immunization strategy in inhibit HCV related liver cancer$167,288
R21 · FY2010 · CA · contact PI
Hepatocarcinogenesis Secondary to Hepatitis C$281,166
R01 · FY2009 · CA · contact PI
Intracellular immunization strategy in inhibit HCV related liver cancer$175,801
R21 · FY2009 · CA · contact PI
Hepatocarcinogenesis Secondary to Hepatitis C$293,416
R01 · FY2008 · CA · contact PI
Hepatitis C Virus and Hepatocellular Carcinoma$337,095
R01 · FY2006 · CA · contact PI
Hepatitis C Virus and Hepatocellular Carcinoma$233,888
R01 · FY2005 · CA
Hepatitis C Virus and Hepatocellular Carcinoma$233,888
R01 · FY2004 · CA
Hepatitis C Virus and Hepatocellular Carcinoma$233,888
R01 · FY2003 · CA
Hepatitis C Virus and Hepatocellular Carcinoma$233,888
R01 · FY2002 · CA
Hepatitis C Virus and Hepatocellular Carcinoma$233,888
R01 · FY2001 · CA
HEPATITIS C VIRUS AND HEPATOCELLULAR CARCINOMA A$244,525
R01 · FY2000 · CA